Fort Myers lab-testing giant promotes pair to C-Suite level roles

Fort Myers-based cancer-focused genetic testing services firm NeoGenomics has promoted two officials to the senior leadership team. 

Warren Stone, who joined NeoGenomics in 2022 as president of Clinical Services, has been promoted to chief commercial officer and will lead NeoGenomics’ clinical and pharma services commercial teams. Stone will be responsible for sales, marketing, pharma project management, commercial enablement, scientific affairs and support functions, according to a release. 

In the other promotion, Melody Harris has been named COO and president, informatics. In this expanded role, Harris will oversee data-oriented teams and manage all enterprise operations, the release adds. Harris joined NeoGenomics in 2022 as president of Enterprise Operations.

“Warren and Melody have shown exceptional leadership and performance in their respective roles," NeoGenomics CEO Chris Smith says in the release. “As we enter our next phase of growth, these senior leadership appointments should drive operational efficiencies, strengthen commercial synergies, and accelerate innovation through R&D. We believe their extensive experience will enhance the operating structure of the organization, thereby improving our service to clinicians and patients.”

NeoGenomics, which specializes in cancer genetics testing and information services, posted $591.46 million in revenue in 2023. The company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development. It also operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services.